MM-349: Teclistamab Plus Daratumumab in Patients With Relapsed/Refractory Multiple Myeloma: Analysis of MajesTEC-3 Based on Cytogenetic and Functional Risk
Rahul Banerjee, Niels WCJ van de Donk, Roberto Mina, María-Victoria Mateos et autres
0 citationsClinical Lymphoma Myeloma & Leukemia